142 related articles for article (PubMed ID: 29277318)
21. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
22. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
24. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
[TBL] [Abstract][Full Text] [Related]
25. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
26. Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2201-2210. PubMed ID: 28741117
[TBL] [Abstract][Full Text] [Related]
27. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
[TBL] [Abstract][Full Text] [Related]
28. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Jiang Z; Woda BA
Adv Anat Pathol; 2004 Nov; 11(6):316-21. PubMed ID: 15505533
[TBL] [Abstract][Full Text] [Related]
30. Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm.
Ynalvez LA; Kosarek CD; Kerr PS; Mahmoud AM; Eyzaguirre EJ; Orihuela E; Sonstein JN; Williams SB
Int Urol Nephrol; 2018 Jan; 50(1):1-6. PubMed ID: 29064003
[TBL] [Abstract][Full Text] [Related]
31. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
32. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
Smit FP; Salagierski M; Jannink S; Schalken JA
BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
[TBL] [Abstract][Full Text] [Related]
33. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Ananthanarayanan V; Deaton RJ; Yang XJ; Pins MR; Gann PH
Prostate; 2005 Jun; 63(4):341-6. PubMed ID: 15602744
[TBL] [Abstract][Full Text] [Related]
34. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
35. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
Alinezhad S; Väänänen RM; Tallgrén T; Perez IM; Jambor I; Aronen H; Kähkönen E; Ettala O; Syvänen K; Nees M; Kallajoki M; Taimen P; Boström PJ; Pettersson K
Urol Oncol; 2016 Jun; 34(6):255.e15-22. PubMed ID: 26857646
[TBL] [Abstract][Full Text] [Related]
36. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ
Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799
[TBL] [Abstract][Full Text] [Related]
37. The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.
Dell'Atti L; Galosi AB
Asian J Androl; 2018; 20(1):15-18. PubMed ID: 28695864
[TBL] [Abstract][Full Text] [Related]
38. alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Kuefer R; Varambally S; Zhou M; Lucas PC; Loeffler M; Wolter H; Mattfeldt T; Hautmann RE; Gschwend JE; Barrette TR; Dunn RL; Chinnaiyan AM; Rubin MA
Am J Pathol; 2002 Sep; 161(3):841-8. PubMed ID: 12213712
[TBL] [Abstract][Full Text] [Related]
39. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Geybels MS; McCloskey KD; Mills IG; Stanford JL
Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
[TBL] [Abstract][Full Text] [Related]
40. Prostate Cancer Diagnosis Using Urine Sediment Analysis-Based α-Methylacyl-CoA Racemase Score: A Single-Center Experience.
Ji J; Chen X; Xu Y; Cao Z; Xu H; Kong C; Wang F; Sun Y
Cancer Control; 2019; 26(1):1073274819887697. PubMed ID: 31793344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
